3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
47
Unknown
21
Recruiting
13
Terminated
7
Withdrawn
4
Not yet recruiting
3
Suspended
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Neoplasms
35
Breast Neoplasms
31
Prostatic Neoplasms
22
Colorectal Neoplasms
21
Leukemia, Myeloid, Acute
19
Pancreatic Neoplasms
17
Melanoma
17
Glioblastoma
16
Carcinoma, Non-Small-Cell Lung
16
Neoplasm Metastasis
15
Lung Neoplasms
13
Brain Neoplasms
13
Glioma
12
Carcinoma, Hepatocellular
12
Stomach Neoplasms
11
Precursor Cell Lymphoblastic Leukemia-Lymphoma
11
Ovarian Neoplasms
10
Myelodysplastic Syndromes
10
Multiple Myeloma
9
Head and Neck Neoplasms
9
Triple Negative Breast Neoplasms
8
Lymphoma
8
Carcinoma, Renal Cell
8
Leukemia
7
Sarcoma
6
Rectal Neoplasms
6
Hematologic Neoplasms
6
Esophageal Neoplasms
6
Uterine Cervical Neoplasms
5
Recurrence
5
Interventions
apatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Suspended
×
Interventional
×
Drug-Related Side Effects and Adverse Reactions
×
Clear all
NCT04824352
2024-05-14
AIEO
Peking University People's Hospital
Phase 2
Suspended
44 enrolled